Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 989 for “"Non-Small Cell Lung Cancer"”.
-
Radiogenomics in non-small-cell lung cancer
Ο μη μικροκυτταρικός καρκίνος του πνεύμονα είναι ο πιο συχνά συναντώμενος υποτύπος καρκίνου του πνεύμονα, ο οποίος αποτελείται από ένα φάσμα υποτύπων. Το NSCLC είναι ένας θανατηφόρος, ετερογενής συμπαγής όγκος με μια εκτεταμένη σειρά μοριακών χαρακτηριστικών. Η πάθηση έχει γίνει ένα αξιοσημείωτο …
-
Radiotherapy in Non-Small-Cell Lung Cancer
Contains fulltext : 30924_radiinnol.pdf (Publisher’s version ) (Open Access)
-
Eosinophils in non-small cell lung cancer
For many years lung cancer has been and, today, still remains one of the principal cancer types across the world. It is also the leading cause of cancer-related death. For those and other reasons detailed in the next section, the burden of lung cancer is even increasing, explaining intensive …
-
Proteome Signatures in Non-Small Cell Lung Cancer
Lung cancer is one of the most common cancers worldwide, and is the top cause of cancer-related death in both men and women. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers and is subdivided into two major histological subtypes: adenocarcinoma (ADC) and squamous cell carcinoma …
-
Neutrophils in advanced non-small cell lung cancer
Lung cancer is the third most common cancer in the UK; 87% are histologically nonsmall cell lung cancer (NSCLC). At the time of diagnosis, patients frequently have advanced disease, with poor one-year survival due to metastatic burden. The immune system should act as a key line of defence; …
-
Enhancing Radiation Sensitivity In Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related death. While radiation therapy is one of the standard treatments for lung cancer, the disease outcome after radiotherapy is still far from satisfactory despite ongoing advances in radiation techniques. Enhancing the radiosensitivity of lung cancer …
-
Investigating Murine Models of Non Small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related mortality worldwide. Adenocarcinoma, the most common subtype is primarily characterized by a combination of p53 and K-ras mutations. The activating K-ras mutation is frequently induced from carcinogens found within tobacco smoke, and is responsible …
-
Human papilloma virus and non small cell lung cancer
ΠΕΡΙΛΗΨΗ ΕΙΣΑΓΩΓΗ: Ο ιός των ανθρώπινων θηλωμάτων (Human Papilloma Virus – HPV ) ανήκει σε μία εξαιρετικά ετερογενή ομάδα επιθηλιοτρόπων DNA ιών με τεκμηριωμένο αιτιολογικό ρόλο στον καρκίνο του τραχήλου της μήτρας και στον καρκίνο κεφαλής- τραχήλου. Η συσχέτιση της λοίμωξης από HPV με τον καρκίνο …
-
Therapeutically targeting autophagy in non-small cell lung cancer
… catabolic pathway which sequesters intracellular components in lysosomes to recycle macromolecules for cell maintenance. The role of autophagy in tumor cells is dynamic and depends on many factors including tumor types, tumor stages, and activity of several tumor suppressors and …
-
Peptide Targeted Drug Delivery to Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a notoriously deadly disease. The integrin αᵥβ₆ is emerging as a viable target for NSCLC; it is expressed in more than half of NSCLC patient tumor samples and only rarely expressed in normal tissue. Importantly, αᵥβ₆ is turned on early in the disease …
-
Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells
Cancer cells display oncogene-driven rewiring of metabolism to produce energy and macromolecules for growth. Inhibition of growth-promoting metabolic pathways may prove to be a useful therapeutic strategy in cancer. However, neither the full breadth of cancer cell metabolic diversity, nor the …
-
ANALYSIS OF IMMUNOREGULATORY BIOMARKERS IN NON-SMALL CELL LUNG CANCER
[EN] Lung cancer is the leading cause of cancer-related death worldwide, and is the third most common cancer type; it can be classified into two subgroups based on histology: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The 5-year survival still remains poor and despite the …
-
The effects of verteporfin on non-small cell lung cancer
Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers and is the leading cause of cancer death in the Unites States. Better treatments must be devised in order to improve the prognosis of this disease. Verteporfin, an FDA approved drug, has recently been reported to downregulate a …
-
Role of neutrophils in metastatic non-small cell lung cancer
Lung cancer is a leading cause of cancer deaths globally. Metastasis, the process by which cancer spreads from its site of origin to a more distant site, accounts for approximately 90% of cancer deaths. Lung cancer is broadly split into non-small cell lung cancer (NSCLC), which represents around …
-
Galectin-3 regulation of non small cell lung cancer growth
… β-galactoside binding lectin expressed in tumour cells and macrophages and has been associated with increased malignancy in a variety of cancers. Previous work has shown that galectin-3 is an important regulator of macrophage function, promoting an alternative (M2) phenotype which potentiates …
-
Identification and Characterization of Non Small Cell Lung Cancer Stem Cells
The discovery of rare tumor cells with stem cell features first in myeloproliferative disease and later in solid tumors has emerged as an important area in cancer research. Through these studies the cancer stem cell model has emerged, which postulates that many tumors are initiated and progressed …
-
Mechanisms of Sensitization to Chemotherapy in Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related deaths world-wide for men and women, due in part to late detection of disease and inherent resistance to treatment. This body of work focuses on resistance to treatment, specifically chemotherapy and understanding ways to sensitize non-small cell …
-
Improving platinum-based treatments for advanced non-small cell lung cancer
… treatments are urgently needed for patients with non-small cell lung cancer (NSCLC). Currently, these patients are almost always first treated with cisplatin (CDDP)-containing drug combinations. To identify therapeutic targets that could enhance CDDP activity, a genome-wide siRNA screen looking …
Page 1 of 50